Cligosiban
Cligosiban ( ; developmental code names IX-01 and PF-3274167) is an oxytocin receptor antagonist which is or was under development for the treatment of premature ejaculation.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cligosiban ( ; developmental code names IX-01 and PF-3274167) is an oxytocin receptor antagonist which is or was under development for the treatment of premature ejaculation. It is taken orally. The drug is a small molecule or non-peptide and is a potent, highly selective, and brain-penetrant antagonist of the oxytocin receptor.
Cligosiban was originated by Pfizer and is under development by Ixchelsis and Chorus Group. As of December 2019, it is in phase 2 clinical trials. However, another source lists the drug's development as having been discontinued.
The drug failed to show effectiveness in a phase 2b trial.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1355707663 under CC BY-SA 4.0; modifications have been made.